The QTGAL Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population specifically engineered to disrupt the QTGAL gene in HEK293T human embryonic kidney cells. This population comprises a heterogeneous mixture of cells harboring a spectrum of loss-of-function mutations generated through CRISPR/Cas9-mediated gene disruption. The polyclonal nature is valuable for pooled functional genomics screens, offering a comprehensive tool to probe the biological significance of QTGAL.
HEK293T cells are a widely utilized derivative of the HEK293 human embryonic kidney cell line, immortalized by transformation with adenovirus 5 DNA and engineered to stably express the SV40 large T antigen. This modification enables high-level episomal amplification of plasmids containing the SV40 origin of replication, making the cell line exceptionally efficient for transient protein expression and viral vector production. Their rapid growth rate, excellent transfection efficiency, and well-characterized epithelial physiology render HEK293T cells a preferred host for a broad range of biomedical research applications, including gene function analysis.
The QTGAL gene product remains functionally uncharacterized, with no validated upstream regulators, downstream targets, or interacting partners reported. Computational predictions tentatively suggest a role in cellular signaling or metabolic regulation, but experimental evidence is lacking. The absence of known pathway associations underscores the value of this knockout model for de novo functional discovery. By generating a heterogeneous pool of QTGAL-disrupted cells, researchers can perform unbiased phenotypic screens to identify cellular processes influenced by this gene, thereby establishing its molecular and physiological context.
Pairing QTGAL knockout with the HEK293T background creates a robust platform for pooled loss-of-function studies. The polyclonal population captures diverse mutational events across the target gene, facilitating the detection of functional domains or critical residues through comparative phenotypic analysis. Given the cell line’s well-documented signaling competence??including intact MAPK, PI3K/AKT, and Wnt pathways??it serves as a suitable system to evaluate potential signaling roles. The model thus bridges the gap between gene disruption and phenotypic readout in a tractable human cellular environment.
This polyclonal knockout product supports diverse research applications, including functional genomics, knockout phenotype screening, and drug target validation. Researchers can employ transcriptomic profiling via RNA-seq, protein analysis by Western blotting, gene expression quantitation with RT-qPCR, flow cytometry for phenotypic marker assessment, and cell viability assays to monitor metabolic or proliferative changes. The integrated use of these techniques enables comprehensive characterization of QTGAL function. For further information, please contact Ascent Research.
